menu
    • menu

    Company profile for Tranquis Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded on groundbreaking immuno-neurology research by Tranquis’ scientific founder, Dr. Edgar Engleman, and his team at Stanford, we are discovering and developing a novel portfolio of small molecule therapeutic candidates which cross the blood-brain barrier to target the underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. Our ambition is to revolutionize the management ...
    Founded on groundbreaking immuno-neurology research by Tranquis’ scientific founder, Dr. Edgar Engleman, and his team at Stanford, we are discovering and developing a novel portfolio of small molecule therapeutic candidates which cross the blood-brain barrier to target the underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. Our ambition is to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Tranquis TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    951 Mariners Island Blvd Suite 300 San Mateo, CA 94404
    Telephone
    Telephone
    +1 650 684-8950
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.tranquis.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/tranquis/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/tranquistx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022
    Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022

    29 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220829005230/en

    BUSINESSWIRE
    29 Aug 2022
    Share Share
    Tranquis Therapeutics Granted FDA ODD for TQS-168 in ALS
    Tranquis Therapeutics Granted FDA ODD for TQS-168 in ALS

    21 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220621005329/en

    BUSINESSWIRE
    21 Jun 2022
    Share Share
    Tranquis Therapeutics concludes Phase I ALS treatment trial
    Tranquis Therapeutics concludes Phase I ALS treatment trial

    03 Jun 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/tranquis-als-treatment-trial/

    CLINICALTRIALSARENA
    03 Jun 2022
    Share Share
    Tranquis Therapeutics Announces Successful Completion of PI Trial of TQS-168
    Tranquis Therapeutics Announces Successful Completion of PI Trial of TQS-168

    02 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220602005937/en

    BUSINESSWIRE
    02 Jun 2022
    Share Share
    Tranquis Therapeutics Announces Participation in March Investor Conferences
    Tranquis Therapeutics Announces Participation in March Investor Conferences

    22 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220322006105/en

    BUSINESSWIRE
    22 Mar 2022
    Share Share
    Tranquis Therapeutics Presents Positive Preclinical Data on TQS-168
    Tranquis Therapeutics Presents Positive Preclinical Data on TQS-168

    03 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211103005909/en

    BUSINESSWIRE
    03 Nov 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search